Every year it’s time for our shot to protect us against flu.
Ok, even as the flu infects every year 10%-20% of the world population and kills around 500.000 people again and again, no one takes this stuff to seriously.
However, maybe this time it’s different.
Because Mexican flu is still hanging around, this year’s flu could be particularly tricky.
The big pharma companies will see sales increases. Big vaccine makers like GlaxoSmithKline could generate additional revenue due to this phenomenon. But unfortunately it will prove not to be substantial for their 40 bln USD budget.
Smaller companies where flu vaccine sales make up a large portion of total revenue however, can profit handsomely.
Take Dutch biotech company Crucell (ticker: CRXL), the seventh largest vaccine maker in the world. There are estimations sales could translate in an extra 40 million USD in revenue. Nice for a company with 400 mnl USD in sales.
Nice…
Sphere: Related Content
Ok, even as the flu infects every year 10%-20% of the world population and kills around 500.000 people again and again, no one takes this stuff to seriously.
However, maybe this time it’s different.
Because Mexican flu is still hanging around, this year’s flu could be particularly tricky.
The big pharma companies will see sales increases. Big vaccine makers like GlaxoSmithKline could generate additional revenue due to this phenomenon. But unfortunately it will prove not to be substantial for their 40 bln USD budget.
Smaller companies where flu vaccine sales make up a large portion of total revenue however, can profit handsomely.
Take Dutch biotech company Crucell (ticker: CRXL), the seventh largest vaccine maker in the world. There are estimations sales could translate in an extra 40 million USD in revenue. Nice for a company with 400 mnl USD in sales.
Nice…
No comments:
Post a Comment